In B-Clear, patients with low baseline HBsAg levels responded best to treatment with bepirovirsen, with 16% of patients on NA therapy and 25% of those taking bepirovirsen achieving clearance of the ...
GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, will get a rapid six-month review from the FDA when it is filed for approval, said the drugmaker this morning. The fast-track ...
Professor J A Madrigal, Anthony Nolan Research Institute, Royal Free Hospital, Pond Street, London NW3 2QG, UK. Email: madrigal{at}rfhsm.ac.uk BACKGROUND/AIMS Clearance of hepatitis B virus (HBV) is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results